Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00899574
First received: May 11, 2009
Last updated: August 19, 2014
Last verified: August 2014

May 11, 2009
August 19, 2014
May 2009
April 2011   (final data collection date for primary outcome measure)
Objective Response (Complete Clinical Response+ Partial Response) [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]
This is defined as percentage of patients who achieved complete clinical response or partial response at end of cycle 1 of treatment. The tumor size will be measured as lesion surface area (region of interest, ROI). The response to the treatment is then evaluated as a function of post-treatment over pre-treatment ROI, expressed in percentage. Response criteria for this study are based on European Organisation for Research and Treatment of Cancer definitions for chest wall tumors: complete clinical response: absence of any detectable residual disease; partial response: <50% of ROI change.
objective response rate [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00899574 on ClinicalTrials.gov Archive Site
Clinical Benefits [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]
This outcome measure is defined as number of patients with improvement of symptoms after 8 weeks of treatment.
  • biological activities of Imiquimod [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • toxicity rate [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
Phase II Evaluation of Imiquimod, a Topical Toll-like Receptor 7 (TLR7) Agonist in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

The purpose of this trial is to determine the safety and efficacy of Imiquimod, a Toll-like receptor 7 agonist in breast cancer (for chestwall recurrences or metastases to the skin).

TLR agonists are novel agents for cancer therapy which modify the immune response. Imiquimod, a synthetic TLR7 agonist has proven immunomodulatory activity when applied topically, leading to clearance of human papilloma virus (HPV)-induced genital warts and primary skin malignancies. Its effects will now be examined in breast cancer metastatic to the skin. If effective, it will add a relatively non-toxic approach to the treatment armamentarium for this patient population frequently resistant to conventional therapies.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Breast Cancer
  • Breast Neoplasms
Drug: Imiquimod

Each treatment cycle consists of 8 weeks.

Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.

Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease.

Other Name: Aldara
Experimental: Imiquimod

Each treatment cycle consists of 8 weeks.

Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.

Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease.

Intervention: Drug: Imiquimod
Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
November 2013
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with biopsy-confirmed breast cancer (prior histological documentation is acceptable).
  • Patients with measurable skin metastases (chest wall recurrence and/or non-chest wall skin metastases are eligible).
  • Skin metastases not suitable for or patient refusing definitive surgical resection and radiation.
  • (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator.

(Cohort 2) Any concurrent systemic therapy is allowed

  • Age at least 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status < or = 2.
  • Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol.
  • Patients must have adequate organ and bone marrow function as defined below:

    • absolute neutrophil count > or = 1,500/microliter
    • hemoglobin > or = 9.5 grams/deciliter
    • platelets >or = 75,000/microliter
    • total bilirubin < or = 1.5 X institutional upper limit of normal
    • Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal
    • creatinine < or = 1.5 X institutional upper limit of normal
  • Informed consent.

Exclusion Criteria:

  • Brain metastases unless resected or irradiated and stable > or = 8 weeks.
  • Treatment with other investigational agents.
  • Patients who have received radiotherapy, high-potency corticosteroids, intralesional therapy, laser therapy or surgery other than biopsy to the target area within 4 weeks prior to first dosing of study agent.
  • Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent.
  • Patients with an uncontrolled bleeding disorder.
  • Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible.
  • Patients with known immunodeficiency or receiving immunosuppressive therapies.
  • History of allergic reactions to imiquimod or its excipients.
  • Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnancy or lactation.
  • Women of childbearing potential not using a medically acceptable means of contraception.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00899574
NYU 09-0225
Yes
New York University School of Medicine
New York University School of Medicine
Not Provided
Principal Investigator: Sylvia Adams, MD New York University School of Medicine
New York University School of Medicine
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP